CAI vs HALO: fair value comparison
Caris Life Sciences, Inc. and Halozyme Therapeutics, Inc. · Updated 2026-10-19
CAI's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, CAI currently ranks higher by quality score.
| CAI | HALO | |
|---|---|---|
| Verdict | Awaiting full valuation | Undervalued |
| Last price | $30.56 | $121.84 |
| 12-month range | $14.55–$32.27 | $61.63–$121.84 |
| Rank by discount to fair value | — | #32 of 108 Healthcare |
| Rank by quality score | #24 of 301 Healthcare | #25 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Moderate | High |
| Margin trend | Expanding | Contracting |
| Revenue growth | High | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Uptrend |
| DCF cross-check | — | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: CAI fair value analysis · HALO fair value analysis